Why the study?
The study was conducted to compare blood pressure and safety outcomes in patients with hypertension initiating bisoprolol versus other beta-blockers, ACE inhibitors or ARBs, CCBs, or diuretics.
Does bisoprolol improve blood pressure and safety outcomes compared to other antihypertensive classes in patients with hypertension?
Does bisoprolol improve blood pressure and safety outcomes compared to other antihypertensive classes in patients with hypertension?
Bisoprolol demonstrates similar blood pressure lowering efficacy and safety profiles compared to other major antihypertensive classes in real-world practice.
Bisoprolol yields comparable BP control and safety to other antihypertensives; leaves open its role versus first-line options in hypertension.
Aim: To compare blood pressure (BP) and safety outcomes in patients with hypertension initiating bisoprolol, versus other β-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium channel blockers or diuretics. Materials & methods: New user cohort study. Patients initiating bisoprolol were matched with up to four patients, in each comparator cohort using propensity score. BP outcomes were compared using linear mixed models and safety outcomes using Cox proportional hazards. Results: Differences in average systolic and diastolic BP variation were ≤3 mmHg between bisoprolol versus the compared classes. No difference was observed in risk of diabetes, obesity or erectile dysfunction. An increased dyslipidemia risk was only observed versus diuretics (hazard ratio: 0.76; 98.75% CI: 0.58, 0.99). Conclusion: No differences in BP variation and safety outcomes.
No takes yet. Share an insight, caveat, or question.
Foch et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: